Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02) "Revacept/CS/02"

Recruiting

Phase 2 Results N/A

Summary of Purpose

Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone. Patients receive a single dose of trial medication by intravenous infusion for 20 minutes. Patients are followed up one and three days after treatment, at 3 months and by a telephone interview at...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 January 2018.

1 Mar 2013 16 Jul 2012 1 Sep 2018 1 Dec 2018 1 Jan 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions See All

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Holger Poppert, PD Dr. med.

    004989-4140-